Sep 30 2009
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share. The traded shares were sold by Barry Allen, President and CEO of Urodynamix Technologies Ltd. who also purchased 2,782,450 common shares at a price of $0.05 per common share through the $1.5 million non-brokered private placement for 30,000,000 common shares that closed on September 25, 2009. All of the shares issued by the Company pursuant to the non-brokered private placement are subject to a 4-month resale restriction and the Company will pay a commission of up to 7.5% on sales of common shares to third parties.
http://www.mdxmedical.com/